Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

Instron® Launches Next Generation Autoinjector Testing System

June 12, 2024

Plus Therapeutics, PPS expand partnership for drug production

The injectable radiotherapy rhenium (186Re) obisbemeda has the potential to minimise risks and enhance outcomes for CNS cancer patients. Credit: fernando zhiminaicela from Pixabay. Plus

May 2, 2023

Switch to Oral Antibiotics Noninferior in Low-Risk Staph Bloodstream Infections

An early switch to oral antibiotics in patients hospitalized with low-risk Staphylococcus aureus bloodstream infection was noninferior to IV antibiotics, according to the randomized controlled

January 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.